Skip to content
Screener

Castle Biosciences CSTL Q1 2025 earnings

Reported May 5, 2025 · After market close

Revenue$88.0MBeat by $16.2M
EPS-$0.20Miss by $0.12
Revenue estimate$71.8M
EPS estimate-$0.08

Next report

Nov 2, 2026 (in a month)
Revenue estimate$92.1M
EPS estimate-$0.38

Financials

Q1 2025

Income statement

See full
Revenue$88.0M+20.6%
Gross profit$71.6M+21.2%
Operating income-$27.9M-410%
Net income-$25.8M-920%
EPS (diluted)-$0.90-900%

Balance sheet

See full
Cash & equivalents$89.7M+8.1%
Total debt$25.8M+3.2%
Total equity$440.3M+9.4%
Total assets$501.7M+9.4%

Cash flow

See full
Operating cash flow-$6.0M+11.7%
CapEx$4.7M-48.2%
Free cash flow-$10.8M+32.6%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$570.85M-6.1%
Enterprise value$507.01M-7.8%
P/S1.6×-0.8×

Profitability

See full
Gross margin81.9%+1.4pp
Operating margin-4%-1.7pp
Net margin-1.5%-0.7pp
FCF margin12%—

Returns & leverage

See full
Return on equity-1.2%-0.6pp
Debt / equity0.1×0.0×
Current ratio9.4×+0.1×

Segments

By product

See full
Dermatologic$63.0M+6.1%
Non-Dermatologic$25.0M+83.5%

By segment

See full
Reportable Segment$88.0M+20.6%

FAQ

When did Castle Biosciences report Q1 2025 earnings?
Castle Biosciences (CSTL) reported Q1 2025 earnings on May 5, 2025 after market close.
What were Castle Biosciences's Q1 2025 revenue and EPS?
Castle Biosciences reported revenue of $88.0M and eps of $-0.20 for Q1 2025.
Did Castle Biosciences beat estimates in Q1 2025?
Revenue beat the consensus estimate of $71.8M by $16.2M. EPS missed the consensus estimate of $-0.08 by $0.12.
How did Castle Biosciences's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 20.6% from $73.0M a year earlier and eps declined 122.2% from $-0.09.
Where can I find Castle Biosciences's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001447362-25-000068) and the 10-Q periodic report (0001447362-25-000069) directly on SEC EDGAR. The filing index links above go to sec.gov.